Furthermore, FAERS includes only cases where AEs occurred rather than complete adverse reaction reports
Summary Keywords Alzheimers disease, clinical trial, cognitive dysfunction, GLP-1 receptor agonist, neuroinflammation, neuroprotection, semaglutide, vascular dementia Citation Alhowail AH, Al Mouslem AK, Almatrafi MA and Aldubayan MA (2026) Semaglutide in cognitive dysfunction: neuroprotective potential, clinical trial limitations, and a prevention-focused framework
In addition, emerging work suggests that specific microbiota-derived secondary bile acids can directly suppress colonic inflammation through epithelial cGMP-PKG signaling (with downstream restraint of mTORC1), providing a mechanistic link between bile acid remodeling and mucosal protection 151
An additional 8 clinics offer cash-pay options for patients without coverage
That translates to tens of millions of people worldwide living with a condition that is only partially understood, frequently dismissed in conventional medical settings, and for which there is currently no FDA-approved treatment
